Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma

被引：0
|
作者：
Sakai, Chio [1 ]
Matsuyama, Masashi [1 ]
Nakajima, Masayuki [1 ]
Matsumura, Sosuke [1 ]
Nonaka, Mizu [1 ]
Arai, Naoki [1 ]
Kuramoto, Kenya [1 ]
Yoshida, Kazufumi [1 ]
Morishima, Yuko [1 ]
Muratani, Masafumi [2 ]
Hizawa, Nobuyuki [1 ]
机构：
[1] Univ Tsukuba, Fac Med, Dept Pulm Med, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Fac Med, Dept Genome Biol, Ibaraki, Japan
来源：
ALLERGOLOGY INTERNATIONAL | 2024年 / 73卷 / 03期
关键词：
D O I：
10.1016/j.alit.2024.03.005
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：473 / 476
页数：4
相关论文
共 50 条
  • [1] Blood Eosinophil Phenotype During Treatment With Mepolizumab in Patients With Severe Eosinophilic Asthma
    Sakai, C.
    Matsuyama, M.
    Nakajima, M.
    Matsumura, S.
    Nonaka, M.
    Arai, N.
    Kuramoto, K.
    Yoshida, K.
    Morishima, Y.
    Muratani, M.
    Hizawa, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [2] Blood eosinophil subtype distribution following treatment with mepolizumab in patients with severe eosinophilic asthma
    Rimkunas, Airidas
    Januskevicius, Andrius
    Vasyle, Egle
    Palacionyte, Jolita
    Jermalaviciene, Inesa
    Miliauskas, Skaidrius
    Malakauskas, Kestutis
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [3] Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
    Ortega, Hector G.
    Liu, Mark C.
    Pavord, Ian D.
    Brusselle, Guy G.
    FitzGerald, J. Mark
    Chetta, Alfredo
    Humbert, Marc
    Katz, Lynn E.
    Keene, Oliver N.
    Yancey, Steven W.
    Chanez, Pascal
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13): : 1198 - 1207
  • [4] Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma
    Albers, Frank C.
    Licskai, Christopher
    Chanez, Pascal
    Bratton, Daniel J.
    Bradford, Eric S.
    Yancey, Steven W.
    Kwon, Namhee
    Quirce, Santiago
    RESPIRATORY MEDICINE, 2019, 159
  • [5] Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma
    Kritikos, Vicky
    Harvey, Erin S.
    Stevens, Sean
    Katelaris, Constance H.
    Langton, David
    Rimmer, Janet
    Farah, Claude S.
    Gillman, Andrew
    Hew, Mark
    Radhakrishna, Naghmeh
    Thomas, Dennis
    Gibson, Peter G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (03): : 885 - +
  • [6] Mepolizumab for the treatment of severe eosinophilic asthma
    Poulakos, Mara N.
    Cargill, Shawna M.
    Waineo, Melissa F.
    Wolford, Allen L., Jr.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (13) : 963 - 969
  • [7] Mepolizumab in the treatment of severe eosinophilic asthma
    Fainardi, Valentina
    Pisi, Giovanna
    Chetta, Alfredo
    IMMUNOTHERAPY, 2016, 8 (01) : 27 - 34
  • [8] GREATER EFFICACY OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA WITH HIGH BASELINE BLOOD EOSINOPHIL COUNTS
    Silver, J.
    Llanos, J.
    Mayer, B.
    Prazma, C.
    Albers, F.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S37 - S38
  • [9] Mepolizumab alters the phenotype and activation status of peripheral blood eosinophils in patients with severe eosinophilic asthma
    Miguens-Suarez, Pablo
    Vazquez-Mera, Sara
    Martelo-Vidal, Laura
    Calvo-Alvarez, Uxio
    Ruiz-Ferreras, Raquel
    Blanco-Aparicio, Marina
    Gonzalez-Fernandez, Coral
    Mosteiro-Anon, Mar
    Dolores Corbacho-Abelaira, Maria
    Mendez-Brea, Paula
    Jose Nieto-Fontarigo, Juan
    Javier Salgado, Francisco
    Javier Gonzalez-Barcala, Francisco
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [10] Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
    Moran, Angela M.
    Ramakrishnan, Sanjay
    Borg, Catherine A.
    Connolly, Clare M.
    Couillard, Simon
    Mwasuku, Christine M.
    Pavord, Ian D.
    Hinks, Timothy S. C.
    Lehtimaki, Lauri
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 202 (09) : 1314 - 1316
12345